United States Patent 9,700,535: Isotretinoin Formulation Claims, Patent Scope, and Generic Entry Risk

U.S. Patent No. 9,700,535 protects a liquid oral isotretinoin dispersion based on micronized drug particles, high-HLB surfactants, co-solvents, and reduced food-effect pharmacokinetics. The strongest claim limitations are the combination of a particle-size threshold, liquid dispersion dosage form, and specified fed/fasted exposure ratios. The patent does not broadly cover all isotretinoin products, capsules, micronized isotretinoin, or reduced-food-effect formulations in isolation.

The principal commercial risk is formulation-specific. A generic product that uses a different particle-size distribution, solid dosage architecture, surfactant system, or pharmacokinetic profile may avoid literal infringement, although it could still face prosecution-history, equivalents, or regulatory challenges.

What does U.S. Patent 9,700,535 protect?

The patent’s independent claims cover oral compositions containing micronized isotretinoin in a liquid vehicle.

Independent claim	Core protected subject matter	Key limitations
Claim 1	Oral pharmaceutical composition	Micronized isotretinoin; d90 not more than 30 microns; dispersion in liquid vehicle; reduced food effect; mean fed/fasted AUC ratio about 1.26; mean fed/fasted Cmax ratio about 1.10
Claim 21	Capsule composition	Micronized isotretinoin; d90 not more than 30 microns; liquid dispersion; reduced food effect; mean fed/fasted Cmax ratio about 1.10

Claim 21 is narrower in dosage form because it expressly requires a capsule, but it does not require the AUC ratio appearing in claim 1. It may therefore capture a capsule product that meets the Cmax limitation but does not demonstrate the claimed AUC ratio.

The claims collectively cover:

Micronized isotretinoin with a d90 of 30 microns or less.
Liquid dispersions rather than conventional solid isotretinoin dosage forms.
Surfactant systems with an HLB value of at least 10.
Co-solvents and oil-free compositions.
Capsule-filled liquid dispersions.
Specific isotretinoin dose ranges and strengths.
Particle-size distributions defined by d90, d50, and d10.
Stability under specified accelerated and long-term storage conditions.
Rapid dissolution at pH 7.8.
Treatment of acne and other specified diseases.

The patent is therefore a formulation and performance patent. It is not a basic compound patent on isotretinoin.

How should claim 1 be construed?

Claim 1 has five material limitations:

The active ingredient must be isotretinoin.
The isotretinoin must be micronized.
The d90 particle-size value must be no more than 30 microns.
The composition must be a dispersion in a liquid vehicle.
The composition must demonstrate the specified reduced food-effect pharmacokinetics.

The particle-size limitation is quantitative. A product with a d90 above 30 microns would fall outside the literal scope of claim 1, assuming the measurement method and particle population are comparable.

The pharmacokinetic language is also important. “Mean fed/fasted ratio of AUC of about 1.26” and “mean fed/fasted ratio of Cmax of about 1.10” are functional and numerical limitations. In an infringement dispute, the parties would likely contest:

The meaning of “about.”
The study population and sample size.
Fed and fasted meal conditions.
Dose normalization.
Statistical treatment of the mean ratios.
Whether the claimed ratios must be demonstrated in the accused product or are inherent in the formulation.
Whether bioequivalence studies can establish the limitation.

A formulation that meets the physical composition limitations but produces materially different fed/fasted ratios may present a noninfringement position. The strength of that position would depend on claim construction and the patent’s prosecution history.

What formulation components are protected?

High-HLB surfactants

Claim 2 requires one or more surfactants having an HLB value of 10 or greater. Claim 5 identifies broad surfactant classes, including:

Polysorbates derived from lauric, palmitic, stearic, and oleic acids.
Polyoxyethylene monoesters.
Polyethoxylated castor oils.
Polyethylene glycol glycerides.
Vitamin E TPGS.
Dioctyl sodium sulfosuccinate.
Sodium lauryl sulfate.
Poloxamers.
Mixtures of these materials.

The HLB limitation narrows the claim to surfactant systems with relatively strong hydrophilic character. A product using a low-HLB surfactant, or relying solely on an oil-based self-emulsifying system, could have a design-around position.

The claim permits a very broad surfactant concentration. Claim 6 recites approximately 1% to 99% by weight, while claim 7 narrows the range to approximately 30% to 80% by weight. These ranges cover highly surfactant-rich liquid systems.

Co-solvents

Claim 8 identifies:

Propylene glycol.
Polypropylene glycol.
Polyethylene glycols.
Diethylene glycol monoethyl ether.
Glyceryl caprylate.
Capric/caprylic glyceride.
Mixtures of these materials.

Claim 2 requires one or more co-solvents and a composition substantially free of oil. The oil-free limitation is commercially significant because many lipid-based isotretinoin systems depend on oils or triglycerides to improve solubilization and absorption.

The term “substantially free of oil” may become a central litigation issue. Small quantities of oily excipients, impurities, or lipidic surfactants could create disputes over whether the composition remains within the claim.

Antioxidants

Claims 9 and 10 cover antioxidant-containing formulations. Listed antioxidants include:

Butylated hydroxyanisole.
Butylated hydroxytoluene.
Tocopherol.
Ascorbyl palmitate.
Ascorbic acid.
Sodium metabisulfite.
Sodium sulfite.
Sodium thiosulfate.
Propyl gallate.

These claims address chemical stability, particularly the susceptibility of isotretinoin to degradation and isomerization. They do not make an antioxidant mandatory for every independent claim because claims 9 and 10 depend from claim 2.

How do the particle-size claims affect infringement risk?

Claims 12 through 16 create a tiered particle-size framework.

Claim	Particle-size limitation
Claim 1	d90 not more than 30 microns
Claim 12	d90 below 30, 25, 20, 15, or 10 microns
Claim 13	d50 below 20, 15, 10, or 5 microns
Claim 14	d50 below 15 microns
Claim 15	d10 below 10, 8, 7, 5, or 2 microns
Claim 16	d10 below 7 microns

The dependent claims create narrower fallback positions around progressively finer micronization. A manufacturer could avoid claims 12, 14, or 16 while still falling within claim 1 if its d90 remains at or below 30 microns.

Particle-size testing requires technical discipline. Results may vary based on:

Laser diffraction versus alternative analytical methods.
Wet versus dry dispersion.
Agglomerate breakup.
Sample preparation.
Refractive-index assumptions.
Batch-to-batch variation.
Whether the measurement concerns the active ingredient before or after formulation.

A design-around program should establish particle-size specifications that remain outside the relevant claim thresholds with a documented analytical margin.

What doses and dosage forms are covered?

Claims 3 and 4 cover isotretinoin amounts from approximately 1 mg to 100 mg, with narrower ranges and listed strengths.

Claimed strength or range	Practical significance
1 mg to 100 mg	Broad dose coverage
5 mg to 50 mg	Intermediate range
10 mg to 40 mg	Common therapeutic range
9 mg to 36 mg	Narrower formulation range
8 mg to 32 mg	Narrower formulation range
8, 16, 20, 24, 28, 32, 36, and 40 mg	Expressly listed strengths

The claims are not limited to a single commercial dose. A capsule containing 8 mg, 16 mg, 24 mg, 32 mg, 36 mg, or 40 mg may fall within the dependent claims if the broader formulation and pharmacokinetic limitations are met.

Claim 11 expressly covers a dispersion filled into capsules. The patent therefore reaches beyond a liquid product administered from a bottle. A softgel or other capsule architecture could be implicated if it contains the claimed liquid dispersion and satisfies the remaining limitations.

What performance requirements are claimed?

Reduced food effect

The key pharmacokinetic limitation is the fed/fasted relationship:

AUC ratio: approximately 1.26 under claim 1.
Cmax ratio: approximately 1.10 under claims 1 and 21.

These ratios indicate that exposure is intended to remain relatively similar between fed and fasted administration. Conventional isotretinoin products have historically been associated with food-dependent absorption, creating commercial value for formulations that reduce the need for administration with a high-fat meal.

The presence of the ratios in the independent claims strengthens the patent’s connection to the demonstrated clinical performance. It also creates potential validity and enforceability questions if the ratios are viewed as poorly defined, insufficiently reproducible, or unsupported across the full breadth of the formulation language.

Dissolution

Claim 20 requires release of more than 50% of isotretinoin within 15 minutes in a medium at pH 7.8. Because claim 20 depends from claim 1, an accused product must first satisfy the claim 1 formulation and pharmacokinetic limitations.

This dissolution limitation may support product testing in an ANDA or litigation setting. It is not an independent dissolution claim covering any rapidly dissolving isotretinoin product.

Stability

Claim 17 requires stability for at least three months at either:

40°C and 75% relative humidity; or
25°C and 60% relative humidity.

The claim is directed to formulation stability rather than manufacturing process protection. A product that lacks the claimed stability profile may have a noninfringement position under claim 17, but claims 1 and 21 do not require the stability limitation.

What diseases and methods of use are covered?

Claim 18 lists numerous treatment indications, including acne, rosacea, psoriasis, cutaneous lupus erythematosus, skin cancer, leukemia, glioma, prostate cancer, lung cancer, and other conditions. Claim 19 narrows the use to acne.

These are composition claims that include intended-use language. The practical value of the treatment limitations depends on claim construction and whether the use language imposes a substantive structural or functional requirement. Claim 19 is commercially relevant because acne is isotretinoin’s primary approved use.

The broad disease list does not create a separate patent monopoly over each disease. It limits the claimed composition by reciting use, but it does not independently protect the underlying medical indication in the same manner as a conventional method-of-treatment claim.

When does U.S. Patent 9,700,535 lose exclusivity?

The patent issued on July 11, 2017. Patent expiration cannot be calculated from the issue date alone. The relevant term generally runs 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments. The claims supplied do not contain the priority chain, term-adjustment certificate, or terminal-disclaimer information needed to state a definitive expiration date. [1]

A practical exclusivity analysis should distinguish:

Exclusivity category	Relevance to this patent
Patent term	Depends on priority and term adjustments
FDA regulatory exclusivity	Depends on the specific isotretinoin product and approval history
Orange Book listing	Depends on whether the patent is listed against an approved product
REMS restrictions	Isotretinoin products are subject to the iPLEDGE-related regulatory framework
Pediatric exclusivity	Product-specific and not established by the claims
Market exclusivity	May end before patent expiry if a valid ANDA challenge succeeds

Patent expiry and FDA exclusivity are separate. A patent may remain in force after regulatory exclusivity ends, and a listed patent may be challenged before its nominal expiration.

What is the Orange Book and Paragraph IV significance?

An Orange Book listing is product-specific. The patent number alone does not establish that U.S. Patent 9,700,535 is currently listed against every isotretinoin product or against any particular brand.

If listed against an approved isotretinoin product, an ANDA applicant could address the patent through:

Paragraph I certification.
Paragraph II certification.
Paragraph III certification.
Paragraph IV certification.
A Section viii statement for a method-of-use patent, where legally available.

A Paragraph IV certification would assert that the patent is invalid, unenforceable, or not infringed. The listed patent holder could file suit within the statutory period, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework. [2]

Because the patent claims formulation characteristics rather than only a labeled indication, a Section viii carve-out may not eliminate all risk. An ANDA product could still infringe composition claims 1 or 21 even if it omits an unprotected indication from its label.

Which generic launch scenarios create the highest risk?

Scenario 1: Same micronized liquid dispersion

Risk is high if the generic uses:

d90 at or below 30 microns;
a liquid vehicle;
high-HLB surfactants;
one of the listed co-solvents;
an oil-free formulation;
similar fed/fasted ratios.

This design could implicate claims 1, 2, 5, 8, and 21.

Scenario 2: Micronized solid capsule

Risk is lower under the supplied claims if the product is a solid suspension, powder-filled capsule, or conventional solid dosage form rather than a liquid dispersion. The d90 limitation alone is insufficient because the independent claims also require a liquid dispersion.

Scenario 3: Oil-based formulation

An oil-based formulation may avoid claim 2’s “substantially free of oil” limitation. It could still face claim 1 or claim 21 if those claims are construed broadly enough to include an oily liquid vehicle, but the absence of the claim 2 limitations would not by itself avoid the independent claims.

Scenario 4: Larger particle size

A formulation with d90 above 30 microns may avoid the principal particle-size limitation. The risk would depend on measurement reliability and whether the product contains a separate micronized fraction that meets the claim.

Scenario 5: Different pharmacokinetic profile

A product that does not produce approximately 1.26 AUC and 1.10 Cmax fed/fasted ratios may have a meaningful noninfringement argument. The argument is strongest if the ratios are treated as mandatory measurable limitations rather than merely evidence of the claimed formulation’s intended performance.

How strong is the patent estate based on the claims?

The patent has moderate composition breadth but narrow technical convergence.

Factor	Assessment
Active ingredient	Narrow to isotretinoin
Particle size	Meaningful limitation, but measurable and design-around capable
Dosage form	Narrowed to liquid dispersion; capsule claim adds commercial relevance
Excipient scope	Broad among high-HLB surfactants and listed co-solvents
Pharmacokinetics	Strong differentiator but potentially vulnerable to measurement and claim-construction disputes
Dissolution	Narrow dependent protection
Stability	Narrow dependent protection
Method of use	Broad indication list, but composition-claim format may limit practical value
Manufacturing protection	No express process claim appears in the supplied claims
Geographic reach	United States only

The strongest enforcement theory would target a product that copies the complete formulation architecture and demonstrates similar fed/fasted pharmacokinetics. The weakest theory would target a product that merely contains isotretinoin or uses micronized isotretinoin without a liquid dispersion.

What manufacturing and intellectual-property barriers exist?

The patent does not expressly claim a micronization process, surfactant manufacturing process, capsule-shell technology, or analytical method. Its barriers are product-based:

Achieving a reproducible d90 below the threshold.
Maintaining isotretinoin stability.
Selecting a non-oily liquid vehicle.
Controlling surfactant concentration and HLB.
Demonstrating rapid release at pH 7.8.
Establishing reduced fed/fasted variability.
Maintaining capsule compatibility and fill uniformity.

A competitor could attempt to design around the patent by changing the dosage form, using a different particle-size profile, selecting a different vehicle, using an oil-containing system, or accepting a conventional food-effect profile.

What litigation and settlement conclusions can be drawn?

The supplied claims do not establish whether U.S. Patent 9,700,535 has been asserted, litigated, settled, disclaimed, reexamined, or challenged through an ANDA Paragraph IV certification. Those events must be evaluated separately from the claim text.

The relevant litigation questions are:

Whether the patent is listed in the Orange Book for a specific isotretinoin product.
Whether an ANDA applicant has served a Paragraph IV notice.
Whether a patent owner filed a Hatch-Waxman infringement action.
Whether a court construed “about,” “substantially free of oil,” and “reduced food effect.”
Whether the claims survived validity challenges involving obviousness, enablement, written description, or indefiniteness.
Whether any settlement permits an authorized generic or delayed generic launch.

No biosimilar pathway applies because isotretinoin is a small-molecule drug. Competitive entry would proceed through the ANDA framework rather than the abbreviated biosimilar pathway. [2,3]

How does this patent compare with conventional isotretinoin patents?

U.S. Patent 9,700,535 differs from basic isotretinoin and conventional product protection in four ways:

Patent category	Typical protected subject	Relationship to U.S. 9,700,535
Compound patent	Isotretinoin molecule	Not the focus of the supplied claims
Conventional formulation patent	Capsule, excipient, or dosage form	9,700,535 requires a specific liquid dispersion architecture
Particle-size patent	Micronized active ingredient	9,700,535 combines particle size with vehicle and PK limitations
Food-effect patent	Reduced fed/fasted variability	9,700,535 incorporates specific exposure ratios into composition claims

The patent’s commercial value is concentrated in products positioned as food-independent or less food-dependent isotretinoin formulations. Conventional isotretinoin capsules that require administration with food may not fall within the claims.

Key Takeaways

U.S. Patent 9,700,535 is directed to micronized isotretinoin liquid dispersions, not isotretinoin generally.
The principal independent-claim combination is d90 of 30 microns or less, liquid dispersion, and specified fed/fasted pharmacokinetics.
Claims 2 through 10 add high-HLB surfactants, co-solvents, oil-free composition, dose ranges, and antioxidants.
Claim 21 separately targets capsule products containing the liquid dispersion and requires the Cmax ratio but not the AUC ratio.
Particle-size testing and the meaning of “about” are likely central technical and legal issues.
Solid, oil-based, larger-particle, or materially different-PK products may offer design-around routes.
The claims supplied do not establish the patent’s definitive expiration date, current Orange Book listing, litigation status, or settlement history.
No biosimilar pathway applies; generic entry would use the ANDA and potentially Paragraph IV process.
The patent has its greatest commercial relevance against copycat liquid isotretinoin dispersion products designed to reduce food effect.

Frequently Asked Questions

Does U.S. Patent 9,700,535 cover all micronized isotretinoin?

No. The supplied independent claims require a liquid dispersion and specified food-effect pharmacokinetics in addition to micronized isotretinoin.

Can a solid isotretinoin capsule avoid the patent?

Potentially. A solid capsule that does not contain isotretinoin dispersed in a liquid vehicle would have a substantial noninfringement position under the supplied claims.

Is an oil-containing isotretinoin formulation automatically outside the patent?

No. Oil may avoid the “substantially free of oil” limitation in claim 2, but claims 1 and 21 must be analyzed separately because they do not expressly contain that limitation.

Does the patent protect isotretinoin manufacturing equipment?

No manufacturing-equipment or manufacturing-process claim appears in the claims supplied. The apparent protection is directed to the finished composition and its performance.

Is a Paragraph IV challenge required for every generic isotretinoin product?

No. The certification strategy depends on the patents listed against the reference product and the scope of the proposed generic’s labeling and formulation. A product that does not infringe a listed formulation patent may submit a Paragraph IV certification asserting noninfringement, while other patents may be addressed through different certifications.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,700,535.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations (Orange Book).
U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-001	Nov 5, 2019		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-002	Nov 5, 2019		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-003	Nov 5, 2019		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-004	Nov 5, 2019		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-005	Nov 5, 2019		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015294993	⤷ Start Trial
Brazil	112017001963	⤷ Start Trial
Canada	2956831	⤷ Start Trial
European Patent Office	3174601	⤷ Start Trial
Japan	2017521470	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,700,535

Which drugs does patent 9,700,535 protect, and when does it expire?

Summary for Patent: 9,700,535